Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: Effect of baseline visual acuity

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 4, 2011, Pages 401-405

  Jonas, Jost B ^a   Tao, Yong ^a,b   Rensch, Florian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXUDATES AND TRANSUDATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 79961202555     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0080     Document Type: Article

References (22)

1. Vingerling, J.R., Dielemans, I., Hofman, A., et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102:205-210, 1995.
2. Rosenfeld, P.J., Moshfeghi, A.A., and Puliafito, C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.Ophthalmic Surg. Lasers Imaging 36:331-335, 2005. (Pubitemid 41073112)
3. Algvere, P.V., Steén, B., Seregard, S., and Kvanta, A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 86:482-489, 2008.
4. Forte, R., Cennamo, G., Finelli, M., et al. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization. Acta Ophthalmol. 88:e305-e310, 2010.
5. Furino, C., Boscia, F., Recchimurzo, N., et al. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration. Acta Ophthalmol. 87:404-407, 2009.
6. Krebs, I., Lie, S., Stolba, U., Zeiler, F., Felke, S., and Binder, S. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol. 87:611-617, 2009.
7. Leydolt, C., Michels, S., Prager, F., et al. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol. 88:594-600, 2010.
8. Mekjavic, P.J., Kraut, A., Urbancic, M., Lenassi, E., and Hawlina, M. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmol. Oct 23, 2009 [Epub ahead of print.]
9. Pedersen, K.B., Sjølie, A.K., and Møller, F. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol. 87:714-719, 2009.
10. Yoon, Y.H., Kim, J.G., Chung, H., and Lee, S.Y. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. Acta Ophthalmol. 87:685-687, 2009.
11. Jonas, J.B., Libondi, T., Ihloff, A.K., et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol. 85:563-565, 2007. (Pubitemid 47163119)
12. Jonas, J.B., Kreissig, I., and Degenring, R.F. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration. Br. J. Ophthalmol. 88:1557-1562, 2004. (Pubitemid 39573597)
13. Sadda, S.R., Stoller, G., Boyer, D.S., Blodi, B.A., Shapiro, H., and Ianchulev, T. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 30:1390-1399, 2010.
14. Rosenfeld, P.J., Shapiro, H., Tuomi, L., et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 118:523-530, 2011.
15. Avery, R.L., Pieramici, D.J., Rabena, M.D., Castellarin, A.A., Nasir, M.A., and Giust, M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, 2006.
16. Bashshur, Z.F., Bazarbachi, A., Schakal, A., Haddad, Z.A., El Haibi, C.P., and Noureddin, B.N. Intravitreal bevacizumab for the management of choroidal neovascularization in agerelatedmacular degeneration.Am. J.Ophthalmol. 142:1-9, 2006. (Pubitemid 43946791)
17. Emerson, M.V., Lauer, A.K., Flaxel, C.J., et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439-444, 2007. (Pubitemid 46624283)
18. Goff, M.J., Johnson, R.N., McDonald, H.R., Ai, E., Jumper, J.M., and Fu, A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular generation. Retina 27:432-438, 2007. (Pubitemid 46624282)
19. Spaide, R.F., Laud, K., Fine, H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390, 2006. (Pubitemid 44197628)
20. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006. (Pubitemid 44511557)
21. Forooghian, F., Cukras, C., Meyerle, C.B., Chew, E.Y., and Wong, W.T. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723-731, 2009.
22. Schaal, S., Kaplan, H.J., and Tezel, T.H. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199-2205, 2008